论文部分内容阅读
目的研究探讨莫沙必利与金双歧联合治疗慢性传输型便秘的临床疗效，总结其临床用药经验与应用价值。方法选取我院2010年6月至2012年6月慢性传输型便秘的患者98例，按照数字表随机抽取法分成2组，各49例，观察组采取莫沙必利与金双歧联合治疗，对照组单纯使用莫沙必利治疗，观察对比两组临床疗效、不良反应及临床症状消退的时间。结果观察组治疗14d后疗效总有效率为93.9%（46/49），药物不良反应为2例，对照组治疗14d疗效总有效率为79.6%(39/49)，药物不良反应为6例，两组疗效与不良反应发生率对比均有显著差异（P＜0.05）；观察组临床症状消退时间要比对照组显著缩短（P＜0.05）。结论莫沙必利与金双歧联合治疗慢性传输型便秘的临床疗效得到肯定，不仅可以提高临床疗效，迅速地缓解便秘相关症状，还能逐步重建与恢复正常的胃肠道功能，缩短疗效以避免单纯莫沙必利长期使用的副反应，安全可靠，值得推广。“,” Objective: To study the clinical effect of mosapride and Golden Bifid in the treatment of chronic transmission constipation, to summarize the clinical experience and application value. Methods: 102 patients in our hospital from 2010 June to 2012 June, the transmission of chronic constipation, according to randomly extraction were divided into 2 groups, each 51 cases, the observation group taking mosapride and Golden Bifid combined treatment, the control group were treated with Mosapride, comparison of two clinical efficacy, adverse reaction and clinical symptoms subsided time. Results: The curative effect of group 14d after treatment the total effective rate was 93.9% (46/49), 2 cases of adverse drug reaction, control efficacy of treatment group total effective rate of 14d was 79.6% (39/49), 6 cases of adverse drug reactions, and the adverse reactions of the two groups curative effect contrast the incidence had significant difference (P<0.05); observation clinical symptoms subsided significantly shorter than the control group (P<0.05). Conclusion: The therapeutic effect of mosapride and Golden Bifid in the treatment of chronic transmission constipation to be sure, not only can improve the clinical efficacy, quickly relieve constipation symptoms, but also gradual y reconstruction and restoration of normal gastrointestinal function, to avoid the simple relationship with curative effect of Mosapride side effects, long-term use of safe and reliable, worthy of promotion.